[go: up one dir, main page]

WO2001098367A3 - Neuroactive peptides for treatment of hypoxia and related conditions - Google Patents

Neuroactive peptides for treatment of hypoxia and related conditions Download PDF

Info

Publication number
WO2001098367A3
WO2001098367A3 PCT/US2001/019839 US0119839W WO0198367A3 WO 2001098367 A3 WO2001098367 A3 WO 2001098367A3 US 0119839 W US0119839 W US 0119839W WO 0198367 A3 WO0198367 A3 WO 0198367A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypoxia
treatment
related conditions
neuroactive peptides
neuroactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019839
Other languages
French (fr)
Other versions
WO2001098367A2 (en
Inventor
Joseph R Moskal
Hirotaka Yamamoto
Patrica A Colley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYXIS Neuro Therapies Inc
Original Assignee
NYXIS Neuro Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NYXIS Neuro Therapies Inc filed Critical NYXIS Neuro Therapies Inc
Priority to CA002413974A priority Critical patent/CA2413974A1/en
Priority to EP01950368A priority patent/EP1296999A2/en
Priority to AU2001271366A priority patent/AU2001271366A1/en
Priority to JP2002504322A priority patent/JP2004500874A/en
Publication of WO2001098367A2 publication Critical patent/WO2001098367A2/en
Publication of WO2001098367A3 publication Critical patent/WO2001098367A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods are provided for the treatment of hypoxia. In a preferred embodiment, compositions and methods are provided for the treatment of the effects of hypoxia or ischemia on the central nervous system.
PCT/US2001/019839 2000-06-22 2001-06-22 Neuroactive peptides for treatment of hypoxia and related conditions Ceased WO2001098367A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002413974A CA2413974A1 (en) 2000-06-22 2001-06-22 Neuroactive peptides for treatment of hypoxia and related conditions
EP01950368A EP1296999A2 (en) 2000-06-22 2001-06-22 Neuroactive peptides for treatment of hypoxia and related conditions
AU2001271366A AU2001271366A1 (en) 2000-06-22 2001-06-22 Neuroactive peptides for treatment of hypoxia and related conditions
JP2002504322A JP2004500874A (en) 2000-06-22 2001-06-22 Neuroactive peptides for the treatment of hypoxia and related conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21361400P 2000-06-22 2000-06-22
US60/213,614 2000-06-22

Publications (2)

Publication Number Publication Date
WO2001098367A2 WO2001098367A2 (en) 2001-12-27
WO2001098367A3 true WO2001098367A3 (en) 2002-08-01

Family

ID=22795793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019839 Ceased WO2001098367A2 (en) 2000-06-22 2001-06-22 Neuroactive peptides for treatment of hypoxia and related conditions

Country Status (5)

Country Link
EP (1) EP1296999A2 (en)
JP (1) JP2004500874A (en)
AU (1) AU2001271366A1 (en)
CA (1) CA2413974A1 (en)
WO (1) WO2001098367A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167314B2 (en) 2009-10-05 2019-01-01 Northwestern University Methods of treating depression and other related diseases

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
JP6419087B2 (en) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド Spirolactam NMDA receptor modulator and use thereof
KR20150110586A (en) 2013-01-29 2015-10-02 노렉스, 인크. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (en) 2013-01-29 2016-04-04 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof.
US9512134B2 (en) 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20151427A1 (en) 2013-01-29 2015-10-10 Naurex Inc SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES
EP3458458B1 (en) 2016-05-19 2020-11-04 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102538803B1 (en) 2016-08-01 2023-06-01 앱티닉스 인크. Spiro-lactam NMDA modulators and methods of use thereof
KR102465758B1 (en) 2016-08-01 2022-11-09 앱티닉스 인크. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP7036792B2 (en) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド Spiro-lactam NMDA receptor modifiers and their use
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2020008107A (en) 2018-01-31 2020-09-25 Aptinyx Inc MODULATORS OF THE NMDA SPIRO-LACTAM RECEPTOR AND THEIR USES.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043306A1 (en) * 1996-05-17 1997-11-20 Neurotherapeutics, L.P. Neuroactive peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043306A1 (en) * 1996-05-17 1997-11-20 Neurotherapeutics, L.P. Neuroactive peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PRIESTLEY T ET AL.: "The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures", BRAIN RESEARCH, vol. 531, 1990, pages 183 - 188, XP002196464 *
RAZDAN B ET AL.: "Modification of the glycine (co-activator) binding site of the N-methyl-D-aspartate receptor in the guinea pig fetus brain during development following hypoxia", BRAIN RESEARCH, vol. 733, 1996, pages 15 - 20, XP002196465 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10167314B2 (en) 2009-10-05 2019-01-01 Northwestern University Methods of treating depression and other related diseases

Also Published As

Publication number Publication date
JP2004500874A (en) 2004-01-15
AU2001271366A1 (en) 2002-01-02
EP1296999A2 (en) 2003-04-02
WO2001098367A2 (en) 2001-12-27
CA2413974A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
WO2001098367A3 (en) Neuroactive peptides for treatment of hypoxia and related conditions
EP1439796B8 (en) Areal implant
AUPQ702900A0 (en) Secure biometric loop
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
AU2002212517A1 (en) Personal authentication system
AU4831500A (en) Authentication
AU2002222194A1 (en) An authentication system
ZA200000079B (en) Driver, fastener and forming tool.
AU2001245537A1 (en) Anti-hypertensive peptides
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
AU2001295483A1 (en) Solid peptide preparations for inhalation, and the production thereof
AU2191401A (en) Benzyl tetralins, formulations and uses thereof
AU6594401A (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
MXPA03001783A (en) N-(3,5-dichloro -2-methoxyphenyl) -4-methoxy-3 -piperazin -1-yl- benzenesulfonamide.
AU2001282453A1 (en) Multi-server authentication
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU2002235883A1 (en) 2-heteroaryl-3,4-dihydro-2H-pyrrole derivatives and the use thereof as pesticides
AU2001252671A1 (en) Pyridobenzodiazine derivatives and processes for the preparation thereof
AU5163000A (en) Strap retainer
WO2000064939A3 (en) Peptides derived from vasostatin i and the use thereof as anti-fungal agents
AU2830401A (en) Amphiphilic polyamines, the use and method for synthesis thereof
AU3440700A (en) Assays, methods and means
AUPQ969200A0 (en) Biometric authentication
EP0827750A3 (en) Obesity protein formulations
WO2003037251A3 (en) Hivgp120-induced bob/gpr15 activation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2413974

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001271366

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 504322

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001950368

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950368

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001950368

Country of ref document: EP